Antithrombin-heparin covalent complex: A possible alternative to heparin for arterial thrombosis prevention

Circulation

Volumn 106, Issue 2, 2002, Pages 261-265

  Chan, Anthony K C ^a   Rak, Janusz ^a   Berry, Leslie ^a   Liao, Peng ^a   Vlasin, Michal ^a   Weitz, Jeffrey ^a   Klement, Petr ^a  

^a NONE   (Canada)

Author keywords

Coronary disease; Fibrin; Heparin; Thrombosis

Indexed keywords

ANTITHROMBIN; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; AORTA THROMBOSIS; ARTERY THROMBOSIS; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFICACY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; THROMBIN TIME;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; AORTA; ARTERIES; FIBRIN; FIBRINOLYTIC AGENTS; HEPARIN; MACROMOLECULAR SUBSTANCES; RABBITS; REGIONAL BLOOD FLOW; THROMBIN; THROMBOSIS;

EID: 0037047084     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000021431.88095.78     Document Type: Article

References (28)

1. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
2. New antithrombotic agents
3. Importance of factor Xa in determining the procoagulant activity of whole-blood clots
4. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II
5. Covalent antithrombin-heparin complexes with high anticoagulant activity: Intravenous, subcutaneous, and intratracheal administration
6. A novel antithrombin-heparin covalent complex: Antithrombotic and bleeding studies in rabbits
7. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model
8. A novel approach to arterial thrombolysis
9. Correlation between structure and function of heparin
10. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
11. Vasoflux, a new anticoagulant with a novel mechanism of action
12. Hirudin in acute myocardial infarction (TIMI)9B Trial
13. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial
14. Hirudin in acute myocardial infarction: Safety report from the TIMI 9A trial
15. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
16. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft leitender kardiologischer Krankenhausärzte
17. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex
18. Importance of factor Xa in determining the procoagulant activity of whole-blood clots
19. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots
20. Electrostatic interactions in the heparin-enhanced reaction between human thrombin and antithrombin
21. The purification and mechanism of action of human antithrombin-heparin cofactor
22. Adverse effect of heparin in thrombin-antithrombin III interaction
23. Effect of heparin on the extent of inhibition of thrombin by heparin cofactor
24. Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma
25. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
26. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation
27. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update
28. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex